Lakewood-Amedex Biotherapeutics Inc. (LABT)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2026-Mar-31
Fiscal PeriodQ1-FY2026
Total Revenue600$
QoQ%
YoY%
Cost Of Revenue507,292$
Gross Profit(506,692$)
Gross Margin(84,448.67%)
Operating Expenses886,750$542,609$
Operating Income(886,750$)(542,609$)
Operating Margin(147,791.67%)
Interest Income1,078$4,307$
Interest Expenses
Income Before Tax(923,291$)(539,617$)
Tax Expenses
Net Income(923,291$)(539,617$)
Profit Margin(153,881.83%)
TTM
Earnings to Minority(2,339,772$)(1,572,424$)
Earnings to Common Shareholders1,416,481$1,032,807$
QoQ%
YoY%37.15%
Earnings Per Share, Basic0.20$0.15$
Earnings Per Share, Diluted0.20$0.15$
Unlevered FCF Per Share, Basic(0.05$)(0.06$)
Unlevered FCF Per Share, Diluted(0.05$)(0.06$)
Average Shares, Basic6,995,4696,943,494
Average Shares, Diluted6,995,4696,943,494
EBIT(923,291$)(539,617$)
EBITDA(923,291$)(539,617$)